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Abstract
Objective—The primary aim is to describe drug and alcohol trajectories in adults with
schizophrenia.
Method—Growth mixture models were used to examine disordered and non-disordered use and
abstinence in the Clinical Antipsychotic Trials of Intervention Effectiveness trial.
Results—Five classes—always abstinent; fluctuating use, abuse, and occasional abstinence;
occasional (ab)use; stopped (ab)use; abusing—fit best. Overlap exists between always abstinent
drug and alcohol classes; less overlap exists across other classes.
Conclusion—There is heterogeneity in drug and alcohol use among adults with schizophrenia.
The lack of overlap between classes, save always abstinent, suggests modeling drug and alcohol
use separately.
© 2013 Elsevier B.V. All rights reserved.
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1. Introduction
Substance use is overrepresented in adults with schizophrenia compared to the general
population (Regier et al., 1990) and increases risk for poor clinical, health, social, and legal
outcomes (Swartz et al., 2006). Despite its high prevalence and deleterious consequences,
substance use remains one of the most vexing clinical complications in this population. This,
in part, may be due to the limited application of advanced statistical approaches, such as
growth mixture modeling (GMM), that describe patterns of substance use over time.
There have been few applications of GMM to explore substance use trajectories in adults
with mental illness (Xie et al., 2006; Xie et al., 2009). A few studies have applied GMM to
examine psychiatric trajectories among adults with mental illness (Chi and Weisner, 2008)
and medication response in adults with schizophrenia (Marques et al., 2011; Muthén and
Brown, 2009). Additionally, studies that have utilized GMMs to investigate substance use
have focused on disordered use or remission as opposed to including non-disordered use.
Prior studies also have focused on patients with diagnosed, co-occurring mental and
substance use disorders, instead of including subjects with subtly reducing or escalating
patterns. Moreover, drug and alcohol trajectories have not been examined separately, though
important differences may exist. Finally, measurement periods have been large, ranging
from six weeks to four years. This study adds to the extant literature by examining drug and
alcohol trajectories using GMMs and horizontal line plots (Tueller, 2013) in a large sample
of adults with schizophrenia.
2. Method
2.1 Sample
Data are from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
study, a randomized clinical trial investigating the cost-effectiveness of atypical and
conventional antipsychotic medications (N=1460). The CATIE study was conducted at over
50 U.S. sites. Only 7% of screened patients were excluded, and the sample resembled a
usual-care, noninterventional sample (Swanson et al., 2006). Study design and entry criteria
are presented elsewhere (Stroup et al., 2003). The CATIE protocol was approved by local
IRBs, and participants gave written informed consent. The RTI International IRB approved
the current study’s protocol.
2.2. Method
2.2.1. Substance use—The CATIE study used a multi-modal approach to assess alcohol
and drug use: (a) SCIDs (First et al., 1996) completed at baseline by MA-level clinicians to
diagnose past month substance use disorders; (b) Alcohol Use Scale and Drug Use Scale
ratings (Drake et al., 1996) completed by an MD or other clinician regarding patients’
substance use during the prior three months; (c) participants’ self-reported alcohol and drug
use during the prior three months; (d) family members/caregivers’ ratings of participants’
problems with excessive drug or alcohol use in the prior month; and (e) biological tests (hair
radioimmunoassay and urinalysis for drug use). Results were used to determine alcohol and
drug abuse/dependence, non-disordered use, and abstinence at each assessment as described
in Van Dorn et al. (2012a) and Desmarais et al. (2012).
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2.2.2. Procedures—The CATIE study included baseline, 1, 3, 6, 9, 12, 15, and 18 month
and end-of-phase assessments.
2.2.3. Analysis—We utilized linear multilevel (clustered by study site) GMMs to examine
intra-individual drug and alcohol trajectories using Mplus 7. GMMs were used to extend the
estimation of inter-individual variation around one average latent growth curve that
describes the intra-individual rate of change in substance use across time. A maximum-
likelihood approach was used to classify participants into different latent trajectory classes,
each representing a different unobserved subpopulation with its own average latent growth
curve. Latent class membership for each participant was estimated by maximizing the
posterior probability of group membership (Muthén, 2001, 2004; Muthén and Shedden,
1999). The Bayesian Information Criterion was used to compare GMMs with different
numbers of classes (Nylund et al., 2007).1 The first class (i.e., always abstinent) was fixed a
priori using the training data option. Within class parameters were constrained to reflect this
lack of variation. All other participants were allowed to be assigned to the first or any other
class.
Missing data were addressed using maximum likelihood estimation assuming missingness at
random (MAR), meaning that missingness assumptions hold after controlling for the
variables that were related to missingness in the model (Enders, 2010). Exploratory analyses
suggested that baseline drug and alcohol values were more strongly predictive of study
attrition than other variables. Because baseline values were part of the model, we assumed
MAR. All cases with at least one observation were included. In each GMM, class
membership was regressed on age, education, sex, minority racial status, and any
hospitalization three months prior to enrollment.
3. Results
Most participants were male (73.9%; n=1,079), white (60%; n=874), not married nor
cohabitating (81.0%, n=1,181), and had completed high school (74.3%, n=1,085). At
baseline, average age was 40.56 years (SD=11.10, range 18–65) and 39.7% (n=579) were
not using, while 60.3% (n=881) reported some substance use.
Five-class models fit best for both drugs and alcohol. Participants were assigned to the class
for which they had the greatest posterior probability of belonging (Lubke and Tueller, 2010).
Figure 1 contains horizontal line plots of participants’ drug and alcohol trajectories stratified
by latent class. White, orange, and red lines designate abstinence, non-disordered use, and
abuse/dependence, respectively. Latent classes and sample sizes within each class were
always abstinent (class 1, drug: n=701, alcohol: n=627); fluctuating use, abuse, and
occasional abstinence (class 2, drug: n=285, alcohol: n=356); occasional (ab)use (class 3,
drug: n=307, alcohol: n=198); stopped (ab)use (class 4, drug: n=62, alcohol: n=220); and
abusing (class 5, drug: n=102, alcohol: n=56). Note that drug users who stopped are in class
3 instead of 4, while alcohol (ab)users who stopped are in the class 4. Variances of the
random intercepts and slopes were smaller in the alcohol models than drug models
indicating greater individual differences in drug than alcohol trajectories.
There was considerable agreement between membership in the always abstinent drug and
alcohol classes: 65.2% of those who always abstained from drugs also always abstained
from alcohol. The next highest level of agreement was between the second classes: 51.6% of
those in the fluctuating use, abuse, and occasional abstinence drug class were in the same
1The bootstrap likelihood ratio tests for testing k vs. k−1 classes are not available when using the training data option in Mplus.
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alcohol class. The greatest discrepancy was found between stopped (ab)use classes: Only
11.8% of those who stopped alcohol (ab)use also stopped drug (ab)use.
Table 1 displays odds ratios (ORs) from regressing class on baseline factors within the
GMMs; using baseline factors to predict class membership in the GMM helps to profile the
unobserved subpopulation represented by each class. Rows contain the target class; columns
contain the reference class. Using drug classes and hospitalization as an example, cases in
class 2 were 2.59 times more likely to have been hospitalized in the 3 months prior to the
baseline assessment than cases in class 1. Overall, the large number of statistically
significant ORs highlights the differences in the likelihood of membership among the five
classes by age, education, sex, minority racial status, and pre-study hospitalization.
4. Discussion
We report new findings from the CATIE study, comparing drug and alcohol trajectories for
adults with schizophrenia identified using GMMs. This represents the first examination of
substance use trajectories in this population. Five latent classes describe patterns of drug and
alcohol use best in these patients: always abstinent; fluctuating use, abuse, and occasional
abstinence; occasional (ab)use; stopped (ab)use; and abusing. There is substantial overlap
between drug and alcohol always abstinent classes; however, overlap between other drug
and alcohol classes was lower. Finally, baseline factors differ between classes as evidenced
by the statistically significant odds ratios in Table 1 describing the differences in the
likelihood of latent class membership by age, education, sex, minority racial status, and pre-
study hospitalization.
Consistent with prior applications of GMM used to examine substance use in other samples
(e.g., adolescents, non-clinical adults) (Chassin et al., 2004), the multiple classes indicate
heterogeneity in substance use over time among adults with schizophrenia. This finding has
important implications for research and practice. First, prior research on substance use
among adults with schizophrenia has assumed homogeneity. Our findings suggest this
assumption is inappropriate and support the need for approaches, such as GMM that model
heterogeneity. Second, there was some within-class heterogeneity (see Figure 1), as seen by
changes in the patterns of abstinence, use, and disordered use over time, indicating the need
for ongoing, repeated assessments. Third, the lack of overlap between drug and alcohol
classes, with the exception of always abstinent, as well as differential outcomes associated
with drug and alcohol use (Van Dorn et al., 2012b), supports modeling drugs and alcohol
separately.
With regard to clinical implications, our findings contribute to a literature supporting
multiple, distinct substance use trajectories, suggesting the need to tailor treatment to
individual patients. As noted above, some patients’ substance use fluctuated (i.e., fluctuating
use, abuse, and occasional abstinence; occasional (ab)use; and stopped (ab)use) whereas
others demonstrated more stability (i.e., always abstinent and abusing). Treatments targeting
individual patterns of use should be most effective, but require ongoing (re)assessment of
use. Findings also support a harm reduction approach that allows for fluctuations in
substance use, as well as consideration of readiness for change, towards the ultimate goal of
abstinence (Kerfoot et al., 2011). For example, for those who transitioned to sustained
abstinence, there were some fluctuations in use prior to sustained abstinence. Finally,
research suggests that integrated treatment for psychiatric and substance use problems will
improve outcomes for patients who demonstrate ongoing use (i.e., fluctuating use, abuse,
and occasional abstinence; occasional (ab)use; and abusing) (Drake et al., 1998).
Overall, our findings suggest multiple trajectories of drug and alcohol use among adults with
schizophrenia, as well as some overlap but also discrepancies between substance use classes.
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Generalizability should be tested against other samples of adults with schizophrenia, as well
as other mental illnesses. Future research also should explore heterogeneity in treatment
response and other distal outcomes based on drug and alcohol trajectories among adults with
schizophrenia (Xie et al., 2010). Growth mixture models represent one way to approach
these important tasks.
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Drug and alcohol trajectories plotted by latent class.
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